Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Other Operating Expenses (2024 - 2025)

Caris Life Sciences has reported Other Operating Expenses over the past 2 years, most recently at $116.1 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $116.1 million for Q4 2025, up 20.04% from a year ago — trailing twelve months through Dec 2025 was $433.4 million (changed N/A YoY), and the annual figure for FY2025 was $440.4 million, up 14.06%.
  • Other Operating Expenses for Q4 2025 was $116.1 million at Caris Life Sciences, up from $110.6 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for CAI hit a ceiling of $116.1 million in Q4 2025 and a floor of $94.0 million in Q3 2024.